AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

Article content

VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, to be held September 30 to October 3, 2026 at the Windsor Oceânico Hotel and Congress Center in Rio de Janeiro, Brazil.

Article content

Details on AbCellera’s oral presentation at IMS are as follows:

Article content

Article content

Title:

Article content

Interim Results of a Phase 1/2 Study of ABCL635, a First-in-Class NK3R Monoclonal Antibody for the Treatment of Vasomotor Symptoms

Article content

Article content

Article content

Abstract ID:

Article content

Article content

16836

Article content

Article content

Session:

Article content

Symptoms of Menopause 1

Article content

Article content

Date and Time:

Article content

Thursday, October 1 from 8:30 a.m. to 9:30 a.m. GMT-3

Article content

Article content

Location:

Article content

Aruba 1, Windsor Oceânico Hotel and Congress Center

Article content

AbCellera will present efficacy and safety data from its Phase 2 trial in postmenopausal women with moderate-to-severe vasomotor symptoms (VMS). The abstract can be viewed online here.

Article content

About ABCL635

Article content

ABCL635 is a potential best-in-class investigational antibody drug for the non-hormonal, long-acting treatment of moderate-to-severe VMS, commonly known as hot flashes, due to menopause. ABCL635 specifically targets NK3R, a clinically validated G protein-coupled receptor (GPCR) expressed on KNDy neurons in the infundibular nucleus of the hypothalamus. ABCL635 is AbCellera’s first pipeline program from the GPCR and ion channel platform to advance into the clinic, in July 2025. Additional details are available at www.abcellera.com/pipeline.

Article content

The Phase 2 trial of ABCL635 (NCT07118891) is a multicenter, randomized, double-blind, placebo-controlled trial in postmenopausal women with moderate-to-severe VMS due to menopause evaluating safety and efficacy of ABCL635.

Article content

About VMS

Article content

Hot flashes and night sweats, known as VMS, are the most common menopausal symptoms, impacting up to 80% of women. The majority rate their VMS as moderate to severe, characterized by intense feelings of heat that lead to sweating, chills, and interrupted sleep. VMS are the most frequent reason for seeking medical care for menopause. VMS can persist for many years after the final menstrual period, and the impact is felt across many aspects of everyday life, including sleep, concentration, energy and mood, work, social activities, and relationships. It is estimated that approximately 12 million women in the US experience moderate-to-severe VMS, of which more than six million seek treatment.

Article content

About AbCellera Biologics Inc.

Article content

Article content

(Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more. For more information, please visit

Article content

Article content

.

Article content

AbCellera Forward-looking Statements

Article content

This document contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this document other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, plans, objectives for future operations, and the evaluation of our available liquidity to execute on our strategy (including our ability to access our reimbursement based R&D government contributions). The use of certain data derived from cross-study comparisons are not based on any head-to-head clinical trials. Cross-study comparisons are inherently limited and may suggest misleading similarities and differences and are presented for informational purposes. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

Article content

Article content

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, other factors, and definition of our business metrics are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this document represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Article content

Article content

Article content

Article content

View source version on businesswire.com:

Article content

Article content

Article content

Contacts

Article content

Inquiries

Article content

Article content

Media: Tiffany Chiu;

Article content

Article content

, +1(236)521-6774

Article content

Article content

Partnering: Murray McCutcheon, Ph.D.;

Article content

Article content

, +1(604)559-9005

Article content

Article content

Investor Relations: Peter Ahn;

Article content

Article content

, +1(778)729-9116

Article content